Chairman and CEO, Ostial Corp.
Independent Board Member since July 2017
Fred Khosravi is a Silicon Valley medical device entrepreneur who has, over the last 25 years, pioneered development of life-saving technologies such as stents and angioplasty devices for coronary artery interventions and life-improving technologies such as intraocular lenses for treatment of cataracts. He cofounded his current company Incept LLC in 1998, where he serves as managing director. Incept was formed to be an effective vehicle for promotion and advancement of technology innovation and entrepreneurship with a primary focus in the life-sciences space and occasional involvement in unique and select information-technology opportunities.
Mr. Khosravi has held senior management positions in both large and small enterprises. He has cofounded 12 medical companies: EndoTex Interventional Systems, Inc., where he developed a novel stent for treatment of carotid arteries as a preventative approach to treat ischemic strokes; Confluent Surgical, Inc., a biomaterials company focused on internal wound-healing solutions for ob-gyn, neuro/spinal, and general surgical applications; Embolic Protection, Inc., focusing on technologies to prevent distal vascular embolization in the brain and the heart to prevent myocardial infarctions and strokes during interventional angioplasty procedures; MarketRx, Inc., a marketing informatics company providing software-based products and services and proprietary analytical models to pharmaceutical, biotechnology, and medical device manufacturers; AccessClosure, Inc., focusing on addressing the unmet need of wound healing during vascular interventional procedures, where he currently serves as chairman of the board; Ostial Corp., a privately held medical device company focused on development of a novel stenting technology for treatment of aorto-ostial disease, where he currently serves as chairman and CEO; Sadra Medical, Inc., a venture-backed medical device company dedicated to developing life-saving and minimally invasive valve technology to treat cardiac-aortic insufficiency; Occular Therapeutix, Inc., a venture-backed medical device company focused on development of innovative and unmet needs of ophthalmic surgery, as well as drug-device combinations for local drug-delivery treatments to the back of the eye; HotSpur, Inc., a start-up medical device company focused on development of innovative technologies for treatment of dialysis grafts and below-the-knee vascular interventions; Nextplane, Inc., an angel-funded company providing secure and scalable federation and management solutions for unified communications (UC) platforms, where he currently serves as chairman of the board; Claret Medical, Inc., a privately held company developing a novel cerebral protection technology to minimize stroke rates associated with minimally invasive and invasive cardiac interventions, where he currently serves as chairman of the board; and Maya Medical, a privately held medical device company addressing the worldwide treatment of hypertension through a novel approach to renal denervation.
Prior to his entrepreneurial career, Mr. Khosravi held senior management positions in large medical device companies such as Guidant Corporation (now part of Abbott) and Alcon Surgical Corp. He is the author or coauthor on over 105 issued or filed patent applications, involving unique and novel medical devices. He holds a B.S. degree in mechanical engineering and graduated cum laude with an M.S. degree in mechanical engineering from Tennessee Tech University. Fred is a Trustee of the Center for International and Strategic Studies (CSIS).